The global ablation devices market size was valued at USD 8.25 billion in 2025 and is projected to grow from USD 9.09 billion in 2026 to USD 19.69 billion by 2034, registering a CAGR of 10.15% during the forecast period (2026-2034). North America dominated the ablation devices market with a share of 38.16% in 2025.
Ablation devices are medical instruments used to remove abnormal tissue through controlled energy delivery. They are classified under HSN Code 9018, particularly 901890 for applicable medical and surgical instruments, and SIC Code 3845 (Electromedical and Electrotherapeutic Apparatus).
The ablation devices market demand is driven by the increasing prevalence of cardiovascular diseases and cancer, along with the adoption of minimally invasive procedures. Technological advancements in ablation systems and expanding hospital treatment capabilities are supporting ablation devices market growth.
Download a Free Sample To learn more about this report,
Preference for Non-Thermal Pulsed Field Ablation
The ablation devices market analysis indicates higher adoption of pulsed field ablation for treating cardiac arrhythmias. This technology uses electrical pulses to target abnormal heart tissue while reducing thermal injury risks. Hospitals are increasingly considering PFA systems for their safety and procedural efficiency. For example, Boston Scientific's MANIFEST-17K study involving 17,642 patients reported major adverse event rates below 1%.
Integration of Cardiac Mapping and Ablation Systems
The integration of cardiac mapping and ablation technologies is becoming an important market trend. Manufacturers are developing systems that combine real-time electrical mapping with precise energy delivery. These integrated platforms help physicians identify abnormal heart signals and improve treatment accuracy.
Supply chain disruptions are expected to have a moderate impact on the ablation devices market share due to shortages of medical-grade components, semiconductors, and specialized catheters. The market is expected to experience a K-shaped recovery, as established manufacturers can restore production faster. Smaller manufacturers may face higher procurement costs and delivery delays. The market is projected to grow at a CAGR of 10.15%. Supply chain constraints could reduce short-term growth by approximately 1.5 percentage points, resulting in a growth of 8.65%.
The ablation devices market forecasts continued investment in pulsed field ablation technologies, clinical trials, and manufacturing expansion.
Key Investment and Funding Activities in Ablation Devices Market, 2025
Increasing Atrial Fibrillation Cases and Clinical Evidence Supporting Ablation as First-Line Treatment Drives Market
High prevalence of atrial fibrillation is increasing demand for catheter ablation procedures. According to the American Heart Association, approximately 10.55 million U.S. adults have atrial fibrillation, accounting for 4.48% of the adult population in 2026. The need for effective rhythm control is encouraging the adoption of catheter ablation over long-term drug therapy in suitable patients. This supports demand for radiofrequency and cryoablation devices across cardiac treatment centers.
Clinical acceptance of catheter ablation as an early treatment option is supporting market growth. European Society of Cardiology guidelines recommend catheter ablation as a first-line rhythm control option for suitable patients with paroxysmal atrial fibrillation. Physician confidence and wider inclusion of ablation in clinical treatment guidelines encourage hospitals to adopt advanced ablation devices.
High Capital Investment and Shortage of Skilled Electrophysiologists Restrain Market Expansion
Ablation procedures require expensive equipment and specialized clinical infrastructure. Hospitals must invest in ablation generators and compatible catheters. Cardiac procedures may also require advanced mapping systems. These requirements increase the financial burden on smaller healthcare facilities.
The limited availability of trained electrophysiologists is restricting the adoption of advanced cardiac ablation devices. Catheter ablation procedures require specialized expertise in cardiac mapping and precise energy delivery. The shortage of qualified professionals limits procedural capacity, particularly in rural hospitals and developing healthcare markets.
Development of Non-invasive Histotripsy Technology and Expanding Application in Thyroid Nodule Treatment Creates Growth Opportunities
Development of histotripsy technology offers opportunities for noninvasive tumor ablation. This technology uses focused ultrasound waves to destroy targeted tissue without thermal energy. The HOPE4LIVER clinical trial reported 95% technical success in 44 treated tumors. Such findings create opportunities for manufacturers to develop advanced ultrasound-based ablation systems for oncology applications.
According to the American Thyroid Association's data, approximately 10–15% of benign thyroid nodules can grow and cause symptoms. The growing interest in nonsurgical treatment options is creating opportunities for specialized ablation devices across endocrinology and outpatient treatment centers.
Radiofrequency dominated the device technoloy segment with a share of 34.20% in 2025 due to established use in cardiac rhythm procedures and precise thermal lesion control. Extensive physician familiarity and compatibility with electroanatomical mapping systems support continued adoption across hospitals.
The pulsed-field segment is likely to witness a CAGR of 16.42% during the forecast period. This growth is driven by non-thermal energy delivery that selectively targets cardiac tissue and reduces risks of damage to surrounding structures.
Request Customizationto receive a tailored report.
In 2025, cardiovascular disease had a share of 31.60, owing to widespread catheter ablation procedures for atrial fibrillation and other cardiac arrhythmias. The need for effective rhythm control supports consistent demand for cardiac ablation devices.
Oncology is projected to undergo growth at a CAGR of 10.76% during the forecast period due to increasing use of image-guided tumor ablation. Clinical application of thermal ablation for localized tumors supports demand for specialized oncology devices.
Hospitals dominated the end user segment with a share of 56.80% in 2025. This dominance is attributed to the availability of specialized electrophysiology laboratories and trained medical professionals. Hospital infrastructure supports complex ablation procedures requiring advanced imaging and continuous patient monitoring.
The ambulatory surgical centers segment is anticipated to record a growth rate of 11.43% during the forecast period, as eligible cardiac ablation procedures shift toward outpatient settings. Expanded Medicare coverage for these procedures supports increased adoption across ambulatory facilities.
Speak to an Analystto discuss market opportunities.
The North America ablation devices market accounted for the largest regional share of 38.16% in 2025.
U.S. Ablation Devices Market
ACC/AHA guidance recommends catheter ablation as first-line therapy for selected symptomatic patients and for appropriate patients with heart failure. This stronger clinical position is expected to increase procedure volumes and support demand for ablation catheters, generators, mapping systems, and electrophysiology accessories used in rhythm-control treatment.
Canada Ablation Devices Market
Ontario Health tracks referrals, procedure volumes, wait times, and intervention rates for atrial fibrillation ablation across hospitals. The province has also increased targeted funding for these procedures. This system-level expansion is expected to strengthen demand for ablation catheters, mapping platforms, generators, and supporting electrophysiology equipment across cardiac centers.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific ablation devices market is expected to grow at a CAGR of 12.18% during the forecast period, showcasing the fastest-growing regional market.
China Ablation Devices Market
National Health Commission recognizes radiofrequency, microwave, cryoablation, focused ultrasound, laser, and irreversible electroporation within its tumor ablation framework. Hospitals must meet defined imaging and procedural requirements. These standards are expected to support wider use of ablation probes, generators, electrodes, and guidance systems in major specialized oncology treatment centers.
India Ablation Devices Market
India is expected to gain from public reimbursement of image-guided tumor ablation. Ayushman Bharat health benefit packages include ultrasound-guided and CT-guided radiofrequency ablation, along with microwave ablation for eligible tumor treatment. Defined package coverage lowers the financial barrier for these minimally invasive procedures. This is expected to support demand for RF generators, microwave systems, probes, antennas, and image-guided ablation accessories across India.
Japan Ablation Devices Market
Japan’s market is expected to benefit from established national reimbursement for advanced cardiac ablation technologies. The Ministry of Health includes dedicated reimbursement categories for pulsed-field ablation catheters used in percutaneous myocardial ablation. This is expected to support demand for ablation catheters, compatible generators, mapping systems, and related procedure equipment nationwide.
The Europe ablation devices market is estimated to register a growth rate of 9.82% during the forecast period.
UK Ablation Devices Market
NICE recommends radiofrequency point-by-point ablation when drug treatment is unsuccessful, unsuitable, or not tolerated, with cryoballoon or laser ablation considered in selected cases. These defined treatment pathways sustain use of multiple ablation modalities and support demand for catheters, generators, mapping systems, and associated electrophysiology supplies across NHS centers.
Germany Ablation Devices Market
National OPS system separately identifies conventional radiofrequency ablation, cooled radiofrequency ablation, cryoablation, and irreversible electroporation for cardiac rhythm disorders. This coding structure supports standardized documentation of different ablation techniques across hospitals.
The Latin America ablation devices market is projected to reach a CAGR of 10.48% during the forecast period. Brazil has added pulsed-field ablation for atrial fibrillation to mandatory private health plan coverage under defined clinical criteria. Broader reimbursement can improve procedure access and strengthen demand for PFA catheters, generators, mapping systems, and supporting electrophysiology equipment.
Mexico is expanding electrophysiology services beyond major tertiary hospitals. IMSS has introduced ablation procedures at a second-level hospital in Morelos and uses advanced mapping technologies at specialized cardiac centers. Greater regional availability of arrhythmia treatment is supporting demand for ablation catheters, generators, three-dimensional mapping systems, and related electrophysiology equipment.
The Middle East & Africa ablation devices market is expected to grow at a CAGR of 9.91% during the forecast period. In the UAE, Al Qassimi Hospital introduced ablation for atrial fibrillation using non-thermal electrical energy. Adoption of this technology expands treatment options and supports demand for PFA catheters, compatible generators, and specialized cardiac ablation equipment.
South Africa is strengthening the clinical pathway for catheter ablation in arrhythmia care. National hospital treatment guidelines recommend referral for curative radiofrequency catheter ablation in patients with frequent or severe supraventricular tachycardia and symptomatic Wolff-Parkinson-White syndrome.
The ablation devices market competitive landscape is moderately consolidated, comprising established medical device manufacturers and specialized ablation technology providers. Key players such as Medtronic, Boston Scientific, Johnson & Johnson, Abbott, AtriCure, and AngioDynamics are estimated to account for 46% of the global ablation devices market share.
Established players compete through advanced ablation technologies, strong distribution networks, clinical expertise, and integrated cardiac mapping systems. Emerging companies in the ablation devices market ecosystem focus on non-thermal energy technologies and specialized ablation catheters.
July 2026: Johnson & Johnson received U.S. FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform.
April 2026: Johnson & Johnson launched VARIPULSE Pro in Europe following CE Mark approval.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Cranial And Facial Implants Market Size, Forecast, Demand, Opportunities, 2034
Arthroscopy Devices Market Size, Forecast, Opportunities, 2034
Coronary Guidewires Market Size, Forecast, Demand, Opportunities, 2034
Coagulation Analyzers Market Size, Forecast, Demand, Opportunities, 2034
Centesis Catheters Market Size, Forecast, Opportunities, 2034
Cardiovascular Diagnostics Market Size, Forecast, Demand, 2034
We are featured on:
sales@straitsresearch.com